Gilotrif (afatinib) / Boehringer Ingelheim 
Welcome,         Profile    Billing    Logout  
 65 Diseases   81 Trials   81 Trials   4890 News 
108 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gilotrif (afatinib) / Boehringer Ingelheim
2017-001284-20: The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif®) in patients with lung cancer 'the BIO-GIO study' Het effect van protonpompremmer esomeprazol op de biologische beschikbaarheid van afatinib (Giotrif®) bij patiënten met longkanker 'de BIO-GIO studie'

Ongoing
4
28
Europe
Coated tablet, Gastro-resistant capsule, afatinib, esomeprazole
Erasmus MC Cancer Institute, Erasmus MC
Non small cell lung cancer Niet-kleincellig longkanker, Lung cancer Longkanker, Diseases [C] - Cancer [C04]
 
 
2019-002197-31: AFAMOSI: Efficacy and safety of afatinib followed by osimertinib compared to osimertinib in patients with EGFRmutated/T790M Mutation negative non-squamous NSCLC. AFAMOSI: Wirksamkeit und Sicherheit von Afatinib gefolgt von Osimertinib verglichen mit Osimertinib bei Patienten mit EGFR-mutiertem/T790M-negativem nicht zu den Plattenepithelkarzinom-zählendem NSCLC.

Not yet recruiting
4
126
Europe
Film-coated tablet, Giotrif, Tagrisso
Universitätsmedizin Mainz, Interdisziplinäres Zentrum klinische Studien, Boehringer Ingelheim Pharma GmbH & Co KG
EGFR mutated non-squamous NSCLC EGFR-mutiertes nicht plattenepithelialen NSCLC, non-small cell lung Cancer (NSCLC) Nicht kleinzelliges Lungenkarzinom (NSCLC), Diseases [C] - Cancer [C04]
 
 
ChiCTR2000029034: Real-world study for sequential therapy with afatinib combined with bevacizumab as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC)

Not yet recruiting
4
84
 
afatinib combined with bevacizumab
National Cancer Center/Cancer Hospital & Shenzhen Hospital; National Cancer Center/Cancer Hospital & Shenzhen Hospital, none
lung cancer
 
 
NCT04356118: Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Not yet recruiting
4
30
NA
Recombinant Human Endostatin, Endostatin, intrathcal methotrexate, Targeted drugs for non-small cell lung cancer
Hui Bu
Leptomeningeal Metastasis
06/23
06/23
ChiCTR2100050095: A single-arm, multi-center, prospective clinical study of recombinant human endostatin injection combined with afatinib maleate tablets and Siggio capsules in the second-line treatment of advanced squamous cell carcinoma of the lung

Not yet recruiting
4
30
 
recombinant human endostatin injection combined with afatinib dimaleate tablets and tegafur, gimeracil and oteracil potassium capsules
The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, China International Medical Exchange Foundation - Simcere Clinical Research Special Fund
advanced lung squamous cell carcinoma
 
 
NCT04814056: To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

Not yet recruiting
4
15
RoW
Afatinib Dimaleate, GIOTRIF®
Shanghai Chest Hospital
NRG1-fused Non-small Cell Lung Cancer
09/23
01/24
NCT04413201: AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

Active, not recruiting
4
34
Europe
Afatinib, Osimertinib
Michael Hopp, Boehringer Ingelheim
Non-squamous NSCLC
12/26
12/26
ACHILLES , jRCTs031180175: study/TORG1834 (study/TORG1834)

Active, not recruiting
3
106
Japan
Gilotrif (afatinib) - Boehringer Ingelheim, cisplatin - Generic mfg., carboplatin - Generic mfg., pemetrexed - Generic mfg.
Niigata Cancer Center Hospital
Advanced non-small cell lung cancer
 
 
CTR20212176: Phase III clinical trial of FHND9041 capsule

Recruiting
3
350
China
FHND9041 - Sino Biopharm, Gilotrif (afatinib) - Boehringer Ingelheim
Jiangsu Zhengda Fenghai Pharmaceutical Co., Ltd.
Non-small cell lung cancer;Oncology
 
 
NCT01853826 / 2009-017661-34: An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Completed
3
481
Europe, RoW
Afatinib, Giotrif®
Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
03/24
03/24
LUX-Head&Neck 3, NCT01856478: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Completed
3
340
RoW
methotrexate, afatinib
Boehringer Ingelheim
Head and Neck Neoplasms
08/18
10/24
FHND9041, NCT06759857: Versus Afatinib for Non-small Cell Lung Cancer

Enrolling by invitation
3
350
RoW
FHND9041, Afatinib
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
03/25
05/25
ERIS, NCT06486142: EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

Recruiting
3
200
Europe
Afatinib/Dacomitinib, Study participants receiving afatinib or dacomitinib until tumor progression/other reasons, Osimertinib, Study participants receiving osimertinib until tumor progression/other reasons
Region Skane, Swedish Lung Cancer Study Group
Non-Small Cell Lung Cancer
09/28
09/28
FHND9041, ChiCTR2100050397: A randomized, open, positives parallel-controlled, multicenter phase III clinical trial to evaluate the efficacy and safety of versus afatinib in first-line treatment of EGFRm+ locally advanced or metastatic non-small cell lung cancer

Recruiting
3
350
 
Afatinib 40mg, orally taken once daily ;FHND9041 80mg, orally taken once daily
Cancer Hospital Chinese Academy of Medical Sciences; Nanjing Chuangte Pharmaceutical Technology Co., Ltd., Self-funded
Non-small cell lung cancer
 
 
NCT02438722: S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Active, not recruiting
2/3
174
US
Afatinib Dimaleate, (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate), BIBW 2992MA2, BIBW2992 MA2, Gilotrif, Cetuximab, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Laboratory Biomarker Analysis
SWOG Cancer Research Network, National Cancer Institute (NCI)
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
09/18
06/25
Drugs-SNPs, NCT05987956: Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms

Not yet recruiting
2/3
600
US
Alectinib - Usual, Usual ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily, Alectinib - Study, Study ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, UnitedHealthcare
Non-small Cell Lung Cancer
11/25
12/25
REAL, UMIN000049225: Rechallenge of afatinib for EGFR mutated non-small cell lung cancer previously treated with osimertinib

Enrolling by invitation
2
30
Japan
Gilotrif (afatinib) - Boehringer Ingelheim
Shinshu University School of Medicine
Non-small cell lung cancer
 
 
WJOG10818L, jRCTs051180009: Trial of the alternative therapy with osimeritinib and afatinib for NSCLC with EGFR mutation (Alt trial)

Completed
2
40
Japan
Tagrisso (osimertinib) - AstraZeneca, Gilotrif (afatinib) - Boehringer Ingelheim
Kindai University Hospital, Department of Medical Oncology, Nippon Boehringer Ingelheim Co., Ltd.
Non-Small Cell Lung Cancer
 
 
YAMATO, jRCTs031200021: A Randomized Phase II Study of Switching Therapy from Afatinib to Osimertinib in the Initial Treatment of Epidermal Growth Factor Receptor (EGFR) Gene Mutation-Positive Non-Squamous Non-Small Cell Lung Cancer (TORG1939/WJOG12919L)

Completed
2
110
Japan
Gilotrif (afatinib) - Boehringer Ingelheim
Kansai Medical University Hospital
Lung cancer
 
 
2006-004528-35: A multicenter, randomized, open label phase II trial evaluating the efficacy and safety of mFOLFOX7 plus weekly alternating sequential oral administration of BIBF 1120 250 mg twice daily and BIBW 2992 50 mg once daily (BB) versus mFOLFOX7 alone as first-line therapy in patients with metastatic colorectal cancer.

Ongoing
2
120
Europe
BIBF 1120, 50 mg, BIBF 1120, 200 mg, BIBW 2992, 5 mg, BIBW 2992, 20 mg, BIBF 1120, BIBW 2992, Capsule, soft, Film-coated tablet, Marca comercial no especificada - Ver sección D.2.2, Marca comercial no especificada- ver sección D.2.2
Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim France SAS, Boehringer Ingelheim España, S.A., , Boehringer Ingelheim España, S.A.
Metastatic colorectal carcinoma, Metastatic colorectal carcinoma Cáncer colo-rectal metastásico., Diseases [C] - Cancer [C04]
 
 
NCT02430727: The Safety and Efficacy Study of Afatinib (CT) Compared With Afatinib (GIOTRIF) in Patients With Solid Tumors (Including Mutations Identified EGFR)

Active, not recruiting
2
148
RoW
Afatinib (CT), BIBW 2992, GIOTRIF, Afatinib
Cancer Centre of Monoclonal Therapy, LLC, Boehringer Ingelheim, NCRI Clinical Studies Groups
Solid Tumors, Glioblastoma
07/15
11/18
2012-004537-16: ABLE Trial – Afatinib Before Lung surgEry

Ongoing
2
69
Europe
Afatinib(Tomtovok), BIBW 2992,
University of Leeds, Boehringer Ingleheim Ltd.
Non-small cell lung cancer
 
 
2014-005364-14: The role of Afatinib to come to radical surgery in patients with non-squamous lung cancer with EGFR gene mutation. Il ruolo di Afatinib per giungere alla chirurgia radicale in pazienti con tumore polmonare non squamoso con mutazione del gene EGFR

Ongoing
2
46
Europe
GIOTRIF 40 MG, GIOTRIF 20 MG, GIOTRIF 30 MG, [GIOTRIF 40 MG], [GIOTRIF 20 MG], [GIOTRIF 30 MG], Coated tablet, GIOTRIF - 40 MG - COMPRESSA RIVESTITA CON FILM - BLISTER DIVISIBILE (PVC/PVDC) 28X1 COMPRESSE, GIOTRIF - 20 MG - COMPRESSA RIVESTITA CON FILM - BLISTER DIVISIBILE (PVC/PVDC) 28X1 COMPRESSE, GIOTRIF - 30 MG - COMPRESSA RIVESTITA CON FILM - BLISTER DIVISIBILE (PVC/PVDC) 28X1 COMPRESSE
ISTITUTO EUROPEO DI ONCOLOGIA, Boehringer Ingelheim
Patients with stage IIIA or stage IIIB N2 requiring neoadjuvant treatment for pN2 non squamous non small cell lung cancer (NSCLC) with EGFR-activating mutations Pazienti con tumore polmonare non a piccole cellule (NSCLC) di tipo non squamoso stadio IIIA o stadio IIIB N2 che richiede un trattamento neoadiuvante pN2 con mutazione attivante del gene EGFR., Patients with non-squamous lung cancer with EGFR gene mutation. Pazienti con tumore polmonare non squamoso con mutazione del gene EGFR, Diseases [C] - Cancer [C04]
 
 
2016-003411-34: Precision 2: an open explorative phase II, open label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation.

Ongoing
2
87
Europe
afatinib, BIBW 2992, Film-coated tablet, GIOTRF
BSMO, UZ Brussel
cancers harbouring an EGFR mutation (excluding non-squamous non- small cell lung cancer, a registered indication), a HER2 mutation or a HER3 mutation, cancers harbouring an EGFR mutation (excluding non-squamous non- small cell lung cancer, a registered indication), a HER2 mutation or a HER3 mutation, Diseases [C] - Cancer [C04]
 
 
ABCD-study, UMIN000030545: Afatinib plus Bevacizumab Combination after osimertinib failure for aDvanced EGFR-mutant non-small cell lung cancer: a multicenter prospective single arm phase II study

Ongoing
2
26
Japan
Gilotrif (afatinib) - Boehringer Ingelheim, Avastin (bevacizumab) - Roche
Hanshin Oncology Group, Boehringer Ingelheim Japan
Advanced EGFR-mutant non-small cell lung cancer
 
 
EAY131-A, NCT06385483: Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Active, not recruiting
2
19
US
Afatinib, BIBW 2992, BIBW-2992, BIBW2992, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
12/22
12/25
2012-000167-25: A multicentric randomized phase II study evaluating dual targeting of the EGFR using the combination of cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer.

Not yet recruiting
2
75
Europe
BIBW2992, AFATINIB, Tablet
UNICANCER, Boerhinger Ingelheim
Refractory wtKRAS metastatic colorectal cancer, Diseases [C] - Cancer [C04]
 
 
TOPGAN2023-01, R000019088: Dose-escalation Study of Afatinib in Elderly Patients with EGFR mutation for Non-Small Cell Lung Cancer

Completed
2
18
Japan
Gilotrif (afatinib) - Boehringer Ingelheim
Hirosaki University Graduate School of Medicine, Hirosaki University Graduate School of Medicine
Non-small cell lung cancer
 
 
The ASCENT Trial, NCT01553942: Afatinib With CT and RT for EGFR-Mutant NSCLC

Active, not recruiting
2
19
US
Afatinib, Radiation, Cisplatin, Pemetrexed, Surgery
Massachusetts General Hospital
Lung Cancer
12/24
12/24
NCT03810872: An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

Recruiting
2
87
Europe
Afatinib, Paclitaxel
AZ-VUB
Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation
12/20
12/22
EAY131-B, NCT04439136: Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Active, not recruiting
2
40
US
Afatinib Dimaleate, (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate), BIBW 2992MA2, BIBW2992 MA2, Gilotrif
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
01/21
03/26
2021-003755-41: ERIS- a national study on characterization of EGFR-positive lung cancer

Not yet recruiting
2
200
Europe
Tablet, VIZIMPRO, GIOTRIF
Region Skåne, Sjöberg Foundation, Kamprad Foundation, The Swedish cancer society
EGFR-mutated non-small cell lung cancer (NSCLC) not amenable for curative treatment intention and candidates for EGFR-inhibitor in first line., Lung cancer with an EGFR-mutation., Diseases [C] - Cancer [C04]
 
 
Neoafa, NCT04470076: Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation

Not yet recruiting
2
30
NA
Neoadjuvant treatment: Afatinib, pemetrexed, gemcitabine, cisplatin, carboplatin, Surgical treatment, Adjuvant treatment:afatinib
Fifth Affiliated Hospital, Sun Yat-Sen University
Non Small Cell Lung Cancer, Surgery, EGFR Activating Mutation, Chemotherapy, EGFR TKI
12/21
07/23
ChiCTR1800019638: Apatinib combined with Docetaxel compared to Docetaxel monotherapy in the treatment of patients with advanced lung squamous cell carcinoma: a prospective, phase II randomized controlled trial

Not yet recruiting
2
200
 
Afatinib and Docetaxel ;Docetaxel
Fujian Tumor Hospital; Fujian Tumor Hospital, Patients at his own expense
squmous cell lung cancer
 
 
AFACET, NCT03727724 / 2018-001521-97: Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer

Completed
2
37
Europe
Afatinib, Cetuximab
The Netherlands Cancer Institute, Boehringer Ingelheim, Merck Serono International SA
Carcinoma, Non-Small-Cell Lung
09/22
09/22
NCT04880811: Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Not yet recruiting
2
43
RoW
Afatinib, Toripalimab
Peking University
Esophageal Squamous Cell Carcinoma
10/22
05/23
TRUMP, NCT03574402: Phase II Umbrella Study Directed by Next Generation Sequencing

Recruiting
2
400
RoW
Avitinib Maleate, AC0010, Afatinib, Giotrif, Crizotinib, Xalkori, X-396, ensartinib, Chidamide, Epidaza, Pyrotinib Maleate, SHR1258, AZD3759, Pirotinib, KBP-5209, Nimotuzumab, Pemetrexed, LY231514, Cisplatin, CDDP, Sintilimab, Gemcitabine, LY188011, Carboplatin, NSC 241240
Guangdong Association of Clinical Trials, Chinese Thoracic Oncology Group
Carcinoma, Non-Small-Cell Lung
12/22
12/24
NCT01522768: Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

Checkmark ASCO-GI 2014
Jan 2014 - Jan 2014: ASCO-GI 2014
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
2
42
US
Afatinib and Paclitaxel
Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, University of Southern California, Dana-Farber Cancer Institute, United States Department of Defense
Esophageal Cancer, Gastric Cancer
02/23
02/23
BEAR, NCT04839471: BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma ( Study)

Completed
2
49
RoW
BI-754091 plus afatinib
National Health Research Institutes, Taiwan, Taipei Veterans General Hospital, Taiwan, Chang Gung Memorial Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
07/23
06/24
MOBILITY3, NCT02506517: A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

Completed
2
12
Canada
Afatinib, GIOTRIF
University Health Network, Toronto, Boehringer Ingelheim
Solid Tumors
05/23
05/23
NCT04183712: Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

Recruiting
2
102
RoW
gemcitabine and oxaliplatin., Gemzar(Eli Lilly and Company) and Aiheng(Jiangsu Hengrui Medicine Co., Ltd.), Afatinib, Gilotrif(Boehringer-Ingelheim)
Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital, Ruijin Hospital, RenJi Hospital, Qilu Hospital of Shandong University, The First Affiliated Hospital of Anhui Medical University, Shanghai East Hospital of Tongji University, Changshu Affiliated Hospital of Soochow University, Qinghai People's Hospital, The Second People's Hospital of Baoshan, Yunnan Province, Lanzhou University Second Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The First People's Hospital of Nantong
Gallbladder Carcinoma
06/25
12/25
NCT03239015: Efficacy and Safety of Precision Therapy in Refractory Tumor

Recruiting
2
300
RoW
Gefitinib, Erlotinib, Afatinib, Trastuzumab, Oxazolidine, Olaparib, Everolimus, Cabozantinib, Vemurafenib, Dabrafenib, Palbociclib, PD-1/L1 inhibitor plus anti-angiogenic agent
Baodong Qin
Rare Tumor, Refractory Tumor
06/23
12/23
NCT03083678 / 2016-002766-31: Afatinib in Locally Advanced and Metastatic Chordoma

Completed
2
43
Europe
Afatinib, Giotrif
Leiden University Medical Center, Chordoma Foundation, Boehringer Ingelheim
Chordoma
01/25
01/25
neoCHANCE-2, NCT05516589: Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC

Recruiting
2
28
RoW
Nab-paclitaxel, Albumin-bound paclitaxel, Abraxane, Cisplatin, CDDP, Tislelizumab, BGB-A317, Afatinib
West China Hospital
Head and Neck Squamous Cell Carcinoma
08/23
08/24
neoCHANCE-1, NCT05517330: Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma

Recruiting
2
23
RoW
Tislelizumab, BGB-A317, Afatinib
West China Hospital
Head and Neck Cancer
08/23
08/24
NCT04533321: A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma

Not yet recruiting
2
20
RoW
Afatinib
National University Hospital, Singapore
Squamous Cell Carcinoma
09/23
09/23
DARWIN1, NCT02183883: Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity

Completed
2
12
Europe
Afatinib, Giotrif
University College, London, Boehringer Ingelheim
Non-small Cell Lung Cancer
03/23
03/23
HER2BAT, NCT04158947: A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone

Recruiting
2
130
RoW
Afatinib, BIBW 2992, T-DM1, Trastuzumab emtansine
xuexin he
HER2-positive Breast Cancer, Brain Metastases
12/23
03/24
NL74383.029.20, NCT05298176 / 2020-003025-37: Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors

Completed
2
5
Europe
Afatinib, Osimertinib, Carboplatin and Pemetrexed
Amsterdam UMC, location VUmc, Boehringer Ingelheim
Non-Small Cell Lung Cancer
04/24
04/24
NCT02122172: Afatinib in Advanced Refractory Urothelial Cancer

Terminated
2
32
US
afatinib dimaleate, afatinib, BIBW 2992 MA2, Gilotrif, laboratory biomarker analysis
University of Chicago, National Cancer Institute (NCI)
Distal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Urethral Cancer, Stage III Bladder Cancer, Stage III Urethral Cancer, Stage IV Bladder Cancer, Stage IV Urethral Cancer, Ureter Cancer
04/24
04/24
NCT02491099: A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

Recruiting
2
50
US
Afatinib, Irreversible Human Epidermal Growth Factor
Yale University, Boehringer Ingelheim
HER2/Neu+ Uterine Serous Carcinoma
07/25
07/25
NCT05215548: Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Active, not recruiting
2
100
RoW
therapeutic thoracic surgery, Afatinib, Giotrif, BIBW 2992
National Taiwan University Hospital
NSCLC Stage IV
10/26
10/27
NCT05070403: Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Recruiting
2
25
US
Afatinib 40 MG
H. Lee Moffitt Cancer Center and Research Institute, Boehringer Ingelheim
Squamous Cell Carcinoma
03/26
03/28
NCT04497584: Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

Recruiting
2
37
US
Afatinib + Prednisone
University of Texas Southwestern Medical Center
Advanced Squamous Non Small Cell Lung Cancer
09/25
09/26
NCT02979977: Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Active, not recruiting
2
50
US
cetuximab, Erbitux, afatinib, GIOTRIF or GILOTRIF
Yale University, National Comprehensive Cancer Network, Boehringer Ingelheim
Squamous Cell Cancers of the Head and Neck
03/25
12/27
NCT05267288: Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Recruiting
2
30
RoW
afatinib, bevacizumab
Qingdao Central Hospital
PFS
12/24
06/25
NCT04410653: Afatinib in Advanced NRG1-Rearranged Malignancies

Completed
2
3
Europe
Afatinib 40 MG
German Cancer Research Center, German Consortium for Translational Cancer Research
Metastatic and Locally Advanced NRG1-rearranged Malignancies
10/23
10/23
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
4200
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
12/27
12/28
NCT06709859: Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Not yet recruiting
2
30
RoW
Afatinib plus chemotherapy as conversion treatment
Shandong Public Health Clinical Center
Carcinoma, Non-Small-Cell Lung
05/26
12/27
NCT06804850: Neoadjuvant Low-Dose Radiotherapy Plus Targeted-Immunotherapy vs Targeted-Immunotherapy Monotherapy in Resectable HNSCC: A Randomized Trial

Recruiting
2
98
RoW
Tislelizumab, Immunotherapy, Afatinib, Targeted therapy, Low dose radiotherapy, Radiotherapy
West China Hospital
Head and Neck Cancer
06/26
06/26
NCT05818982: To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC

Recruiting
2
72
RoW
Afatinib, Irinotecan
Peking University
Advanced Esophageal Squamous Cell Carcinoma
02/25
02/26
NCT05865132: Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

Recruiting
2
30
RoW
Palbociclib, Afatinib
AIPING ZHOU
Esophagus Squamous Cell Carcinoma
04/25
04/26
UPSTREAM, NCT03088059 / 2017-000086-74: Biomarker-based Study in R/M SCCHN

Checkmark Data from UPSTREAM trial in combination with monalizumab for SCCHN
Oct 2019 - Oct 2019: Data from UPSTREAM trial in combination with monalizumab for SCCHN
Active, not recruiting
2
340
Europe
Afatinib, Palbociclib, standard of care, IPH2201, Monalizumab, Durvalumab, Niraparib, INCAGN01876
European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma, Squamous Cell of Head and Neck
06/25
12/25
NCT05519917: Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma

Not yet recruiting
2
20
RoW
Afatinib
Huashan Hospital, Boehringer Ingelheim
Chordoma of Clivus
06/25
12/25
NCT05588609: Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Active, not recruiting
2
90
US
Afatinib Oral Tablet, GILOTRIF®, GIOTRIF®, Enzalutamide Pill, XTANDI®, Abiraterone acetate tablets, ZYTIGA®, MCLA-128, Zenocutuzumab
Merus N.V.
NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
10/25
03/26
NCI-MATCH, NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Checkmark Approved in combination with Trametinib for adult and pediatric patients with BRAF V600E solid tumors
Jan 2023 - Jan 2023: Approved in combination with Trametinib for adult and pediatric patients with BRAF V600E solid tumors
Checkmark Approved in combination with for Mekinist for BRAF V600E solid tumors
Jun 2022 - Jun 2022: Approved in combination with for Mekinist for BRAF V600E solid tumors
Checkmark Results from arm Z1D-a subprotocol of the NCI-MATCH study in mismatch repair-deficient non-colorectal cancers
More
Active, not recruiting
2
6452
US, RoW
Adavosertib, AZD 1775, AZD-1775, AZD1775, MK 1775, MK-1775, MK1775, Afatinib, BIBW 2992, BIBW-2992, BIBW2992, Afatinib Dimaleate, (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate), BIBW 2992MA2, BIBW2992 MA2, Gilotrif, Binimetinib, ARRY 162, ARRY 438162, ARRY-162, ARRY-438162, ARRY162, ARRY438162, MEK 162, MEK-162, MEK162, Mektovi, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capivasertib, AZD 5363, AZD-5363, AZD5363, Truqap, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Copanlisib, BAY 80 6946, BAY 80-6946, BAY 806946, BAY-80-6946, BAY806946, PI3K Inhibitor BAY 80-6946, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Crizotinib, Alkixen, Crizocent, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Dabrafenib, BRAF Inhibitor GSK2118436, GSK 2118436, GSK 2118436A, GSK-2118436, GSK-2118436A, GSK2118436, GSK2118436A, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Defactinib, PF-04554878, VS-6063, Defactinib Hydrochloride, Echocardiography Test, EC, Echocardiography, Erdafitinib, Balversa, JNJ 42756493, JNJ-42756493, JNJ42756493, Fexagratinib, ABSK-091, ABSK091, AZD4547, FGFR Inhibitor AZD4547, KB-74810, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Laboratory Biomarker Analysis, Larotrectinib, ARRY 470, LOXO 101, LOXO-101, LOXO101, Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Osimertinib, AZD 9291, AZD-9291, AZD9291, Mereletinib, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, PD0332991, Pertuzumab, 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440, PI3K-beta Inhibitor GSK2636771, GSK-2636771, GSK2636771, Radiologic Examination, Radiologic Evaluation, Radiologic Exam, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Relatlimab, BMS 986016, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer, Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228, Sunitinib Malate, SU 011248, SU 11248, SU-011248, SU-11248, SU011248, SU11248, sunitinib, Sutent, Taselisib, GDC-0032, RO5537381, Trametinib, GSK 1120212, GSK 212, GSK-1120212, GSK-212, GSK1120212, GSK212, JTP 74057, JTP-74057, JTP74057, MEK Inhibitor GSK1120212, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, HLX 02, HLX-02, HLX02, Kanjinti, Ogivri, Ontruzant, PF 05280014, PF-05280014, PF05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO 132365, PRO-132365, PRO132365, RO5304020, T-DM1, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Ulixertinib, BVD-523, VRT752271, Vismodegib, Erivedge, GDC 0449, GDC-0449, GDC0449, Hedgehog Antagonist GDC-0449
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
12/25
12/25
NCT06071013: Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Not yet recruiting
2
20
NA
Nintedanib, gefitinib, erlotinib, afatinib
China Medical University Hospital
Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation
08/26
08/26
NCT06062823: Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

Recruiting
2
35
RoW
Afatinib 40 MG, Gilotrif
National University Hospital, Singapore
NSCLC
10/26
12/26
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
2015-001477-41: BI 1361849 (CV9202) + afatinib compared with placebo + afatinib in first-line NSCLC harbouring common EGFR mutations BI 1361849 (CV9202) + afatinib comparado con placebo + afatinib como tratamiento de primera línea en pacientes con NSCLC portadores de mutaciones comunes del EGFR.

Ongoing
1/2
120
Europe
BI 1361849, Afatinib, BI 1361849, BIBW 2992, Powder and solvent for solution for injection, Film-coated tablet, GIOTRIF 20 mg film-coated tablets, GIOTRIF 30 mg film-coated tablets, GIOTRIF 40 mg film-coated tablets
Boehringer Ingelheim España, S.A., Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim España, S.A., Boehringer Ingelheim Pharma GmbH & Co. KG
Advanced non-small cell lung cancer (adenocarcinoma) stage IV. Cáncer de pulmón no microcítico metastásico (adenocarcinoma) estadio IV ., Advanced lung cancer with metastases. Cáncer de pulmón avanzado con metástasis., Diseases [C] - Cancer [C04]
 
 
CamBMT1, NCT02768337: Cambridge Brain Mets Trial 1

Terminated
1/2
26
Europe
Afatinib, Giotrif, 2 Gy targeted radiotherapy, 4 Gy targeted radiotherapy
Cambridge University Hospitals NHS Foundation Trust, Boehringer Ingelheim, Cancer Research UK, University of Cambridge, The Brain Tumour Charity
Lung Cancer, Breast Cancer, Brain Cancer, Advanced Breast Cancer, Advanced Lung Cancer
08/20
08/21
KRYSTAL-1, NCT03785249: Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation

Jul 2023 - Sep 2023: Approval in EU for 2L+ NSCLC
Checkmark Approved for 2L KRASG12C-mutated locally advanced or metastatic NSCLC based on KRYSTAL-1 study
Dec 2022 - Dec 2022: Approved for 2L KRASG12C-mutated locally advanced or metastatic NSCLC based on KRYSTAL-1 study
Checkmark Data from KRYSTAL-1 trial for colorectal cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from KRYSTAL-1 trial for colorectal cancer at ESMO 2022
More
Recruiting
1/2
822
US
MRTX849, Pembrolizumab, Cetuximab, Afatinib
Mirati Therapeutics Inc.
Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
07/25
01/26
AFAN, NCT06648096: Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Not yet recruiting
1/2
25
Europe
Afatinib
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, MFAR Clinical Research S.L.
Fanconi Anemia, Head and Neck Squamous Cell Carcinoma
12/28
12/28
NCT06753747: A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

Not yet recruiting
1/2
45
RoW
Palbociclib, Afatinib(30mg), Afatinib(40mg), Afatinib(RP2D)
West China Hospital
Esophagus Cancer
04/27
04/28
NCT06085755: Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

Recruiting
1/2
61
RoW
Trastuzumab deruxtecan, T-DXd, Afatinib, Giotrif
Jeeyun Lee
Stomach Neoplasm
12/25
12/26
CSWOG2019001, ChiCTR1800020396: Afatinib combined with Docetaxel compared to Docetaxel or afatinib monotherapy in the treatment of patients with advanced lung squamous cell carcinoma: a prospective, phase II randomized controlled trial

Not yet recruiting
1
244
 
Afatinib combined Docetaxel ;Afatinib ;Docetaxel
Fujian Tumor Hospital; Fujian Tumor Hospital, at his own expense
squamous cell lung carcinoma
 
 
NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Recruiting
1
48
RoW
JMT101, Afatinib or Osimertinib
Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
12/21
06/22
DPTA, NCT03827070: Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma

Active, not recruiting
1
12
RoW
Afatinib, BIBW2992, Talcum powder, Talc
Center Trials & Treatment Europe, Center Trials & Treatment
Non Small Cell Lung Cancer
02/23
07/23
NCT05164848: JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy

Recruiting
1
50
RoW
JMT101, Afatinib
Peking University
Esophageal Squamous Carcinoma
10/23
10/23
NCT06302621: Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Recruiting
1
70
US
Afatinib, Gilotrif™, Pemigatinib, Pemazyre
Massachusetts General Hospital, Boehringer Ingelheim, Incyte Corporation
Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Cholangiocarcinoma
12/24
12/25
NCT06494189: Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

Recruiting
1
29
RoW
Tislelizumab, Afatinib, Low dose radiotherapy
West China Hospital
Head and Neck Cancer
07/25
12/25
NCT06741982: A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

Recruiting
1
21
RoW
Lysogenic HSV virus., Biological agent, Tislelizumab, Immunotherapy, Afatinib, Targeted therapy
West China Hospital
HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy, Targeted Therapy
12/26
12/26
EDDIS-a1, NCT06897735: Exploratory Study of Inhaled Afatinib Dimaleate PK Profile

Not yet recruiting
1
24
RoW
Afatinib Dimaleat, BIBW2992 Dimaleate, Gilotrif, Afatinib Dimaleate, inhalation of afatinib dimaleate
Petrov, Andrey
Lung Cancer, Oral Cancer, Melanoma
06/25
07/25
NCT05927844: XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma

Not yet recruiting
1
20
NA
XH-30002 capsule, Afatiinb tablet
Fujian Cancer Hospital
Esophageal Squamous Cell Carcinoma
06/25
06/25
SMMART, NCT03878524: Serial Measurements of Molecular and Architectural Responses to Therapy () PRIME Trial

Terminated
1
2
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Abiraterone, CB 7598, Afatinib, BIBW 2992, BIBW2992, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Zirabev, Anti-VEGF Monoclonal Antibody SIBP04, SIBP 04, SIBP-04, SIBP04, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Biospecimen Collection, Biological Sample Collection, Specimen Collection, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Cabozantinib, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, 934660-93-2, Copanlisib, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Dacomitinib, EGFR Inhibitor PF-00299804, PF-00299804, PF-00299804-03, PF-299804, Vizimpro, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, 1297538-32-9, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, 1428935-60-7, Enasidenib, AG-221, CC-90007 Free Base, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Enzalutamide, ASP9785, MDV3100, Xtandi, Erlotinib, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Idelalisib, CAL-101, GS 1101, GS-1101, Phosphoinositide-3 Kinase Delta Inhibitor CAL-101, Zydelig, Imatinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Leucovorin, Folinic acid, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, PF-06463922, Losartan, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Neratinib, (2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, HKI 272, HKI-272, PB 272, PB-272, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Panobinostat, Faridak, LBH589, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pertuzumab, 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, HLX11, Ponatinib, AP-24534, AP24534, Quality-of-Life Assessment, Quality of Life Assessment, Regorafenib, BAY 73-4506, REGORAFENIB ANHYDROUS, Stivarga, Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Sorafenib, BA4 43 9006, BAY 43-9006, Bay-439006, Sunitinib, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Tretinoin, 2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-, Aberel, Airol, Aknoten, all trans-Retinoic acid, All-trans Retinoic Acid, All-trans Vitamin A Acid, all-trans-Retinoic acid, all-trans-Vitamin A acid, ATRA, Avita, beta-Retinoic Acid, Cordes Vas, Dermairol, Epi-Aberel, Eudyna, Renova, Retin-A, Retin-A MICRO, Retin-A-Micro, Retinoic Acid, Retisol-A, Ro 5488, Stieva-A, Stieva-A Forte, Trans Retinoic Acid, Trans Vitamin A Acid, trans-Retinoic Acid, Tretinoinum, Vesanoid, Vitamin A Acid, Vitamin A acid, all-trans-, Vitinoin, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
OHSU Knight Cancer Institute, Oregon Health and Science University
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
12/20
12/20
CodeBreak101, NCT04185883 / 2020-004721-23: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Checkmark Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Checkmark Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Checkmark Presentation of data from CodeBreak 101 and CodeBreak 100 in combination with Keytruda and Tecentriq for 2L NSCLC at IASLC-WCLC 2022
More
Recruiting
1
1200
Europe, Canada, Japan, US, RoW
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Amgen, Amgen Inc, Amgen Inc.
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
06/26
12/27
NCT05432518: Pilot Trial for Treatment of Recurrent Glioblastoma

Recruiting
1
10
Canada
Afatinib, Giotrif, Dasatinib, Sprycel, Palbociclib, Ibrance, Everolimus, Teva-everolimus, Olaparib, Lynparza
AHS Cancer Control Alberta, Tom Baker Cancer Centre
Glioblastoma, Recurrent Disease, Recurrent Glioblastoma
07/27
12/27
ChiCTR2200067154: Bioequivalence study of Afatinib maleate tablets

Completed
N/A
32
 
The selected subjects entered the Phase I ward 1 day before the first cycle of the test, and the subjects fasted for at least 10 hours ning of the administration day, the test preparation was orally adminiovernight before taking the drug. After a blank blood sample was collected in the morsterermd. ;The selected subjects entered the Phase I ward 1 day before the first cycle of the test, and the subjects fasted for at least 10 hours overnight before taking the drug. After a blank blood sample was collected in the morning of the administration day, the reference preparation was orally administere
Shanghai Pudong New Area People's Hospital; Shanghai Pudong New Area People's Hospital, Jiangxi Shanxiang Pharmaceutical Co., Ltd.
NA
 
 
Gio-Tag Japan, UMIN000037452: Japanese A Multicenter Prospective Observational Study to Evaluate the Efficacy of Sequential Administration From Afatinib to Osimertinib in EGFR Mutation-Positive Non-Small Cell Lung Cancer

Recruiting
N/A
120
Japan
Gilotrif (afatinib) - Boehringer Ingelheim, Tagrisso (osimertinib) - AstraZeneca
HANSHIN Oncology Group, Boehringer Ingelheim
Non-small cell lung cancer
 
 
ChiCTR1800018149: A multicentre, open-label, randomised, controlled trial for the effect and safety of Afatinib with Nivolumab in the treatment of gallbladder carcinoma with ERBB2/3 mutation

Not yet recruiting
N/A
522
China
treating with Afatinib and Nivolumab ;treating with Afatinib ;treating with GEMOX
Xinhua Hospital affiliated to Shanghai Jiaotong University, School of Medicine ; Xinhua Hospital affiliated to Shanghai Jiaotong University, School of Medicine, Shanghai Hospital Development Center
gallbladder carcinoma
 
 
ChiCTR2100047133: Multicentre, prospective, real-world clinical study of afatinib or gefitinib in combination with first-line chemotherapy for advanced EGFR mutant non-squamous NSCLC

Recruiting
N/A
1000
 
Nil ;Nil
Shandong Cancer Hospital; Shandong Cancer Hospital, Qilu Pharmaceutical Co., Ltd
Lung cancer
 
 
ChiCTR1900024983: A non-interventional, single-arm, prospective clinical study for the efficacy and safety of low-dose alfaatinib combined with pemetrexed and carboplatin in first-line treatment of advanced EGFR mutant non-squamous non-small cell lung cancer

Recruiting
N/A
100
 
Afatinib, Pemetrexed and Carboplatin
Shandong Cancer Hospital; Shandong Cancer Hospital, Self-finance
Lung Cancer
 
 
NCT05107193: Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)

No Longer Available
N/A
NA
afatinib, GILOTRIF®
Boehringer Ingelheim
Solid Tumors
 
 
NCT03908892: Effect of Zanthoxylum Nitidum Tincture for Paronychia Caused by Afatinib

Recruiting
N/A
110
RoW
zanthoxylum nitidum tincture, tetracycline ointment
Guangzhou University of Traditional Chinese Medicine
Paronychia
12/22
12/22
BELLA, NCT04575415: Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

Recruiting
N/A
272
RoW
Bevacizumab, Avastin, Erlotinib, Tarceva, Gefitinib, Iressa, Icotinib, Conmana, Afatinib, Gilotrif, Dacomitinib, Vizimpro, Osimertinib, Tagrisso
Guangdong Association of Clinical Trials
NSCLC
05/23
12/23
ChiCTR2000034451: Bevacizumab combined with afatinib for first-line treatment of locally advanced or advanced EGFR mutation-positive NSCLC patients: the effectiveness and safety database management platform construction project

Not yet recruiting
N/A
50
 
afatinib combined with bevacizumab
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Association of Oncology
NSCLC
 
 
NCT04795245: Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Completed
N/A
805
Japan
afatinib, Giotrif®
Boehringer Ingelheim
Non-squamous, Non-Small Cell Lung Cancer
10/23
10/23
START, NCT04206787: The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

Completed
N/A
72
RoW
Afatinib, Giotrif®
Boehringer Ingelheim
Non-squamous, Non-Small Cell Lung Cancer
12/23
12/23
ChiCTR2200057280: Efficacy and safety of low-dose afatinib combined with bevacizumab and pemetrexate in first-line treatment of stage IV lung adenocarcinoma with EGFR mutation

Recruiting
N/A
100
 
low-dose alfaatinib combined with bevacizumab and pemetrexed
Shandong Cancer Hospital; Shandong Cancer Hospital, self-funded
Lung Cancer
 
 
ChiCTR2100042399: Anlotinib combined with afatinib in the third-line treatment of advanced lung squamous cell carcinoma

Not yet recruiting
N/A
35
 
Anlotinib combined with afatinib
Cancer Center of Yibin Second People's Hospital; Cancer Center of Yibin Second People's Hospital, None
Lung squamous cell carcinoma that failed second-line chemotherapy
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gilotrif (afatinib) / Boehringer Ingelheim
2017-001284-20: The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif®) in patients with lung cancer 'the BIO-GIO study' Het effect van protonpompremmer esomeprazol op de biologische beschikbaarheid van afatinib (Giotrif®) bij patiënten met longkanker 'de BIO-GIO studie'

Ongoing
4
28
Europe
Coated tablet, Gastro-resistant capsule, afatinib, esomeprazole
Erasmus MC Cancer Institute, Erasmus MC
Non small cell lung cancer Niet-kleincellig longkanker, Lung cancer Longkanker, Diseases [C] - Cancer [C04]
 
 
2019-002197-31: AFAMOSI: Efficacy and safety of afatinib followed by osimertinib compared to osimertinib in patients with EGFRmutated/T790M Mutation negative non-squamous NSCLC. AFAMOSI: Wirksamkeit und Sicherheit von Afatinib gefolgt von Osimertinib verglichen mit Osimertinib bei Patienten mit EGFR-mutiertem/T790M-negativem nicht zu den Plattenepithelkarzinom-zählendem NSCLC.

Not yet recruiting
4
126
Europe
Film-coated tablet, Giotrif, Tagrisso
Universitätsmedizin Mainz, Interdisziplinäres Zentrum klinische Studien, Boehringer Ingelheim Pharma GmbH & Co KG
EGFR mutated non-squamous NSCLC EGFR-mutiertes nicht plattenepithelialen NSCLC, non-small cell lung Cancer (NSCLC) Nicht kleinzelliges Lungenkarzinom (NSCLC), Diseases [C] - Cancer [C04]
 
 
ChiCTR2000029034: Real-world study for sequential therapy with afatinib combined with bevacizumab as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC)

Not yet recruiting
4
84
 
afatinib combined with bevacizumab
National Cancer Center/Cancer Hospital & Shenzhen Hospital; National Cancer Center/Cancer Hospital & Shenzhen Hospital, none
lung cancer
 
 
NCT04356118: Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Not yet recruiting
4
30
NA
Recombinant Human Endostatin, Endostatin, intrathcal methotrexate, Targeted drugs for non-small cell lung cancer
Hui Bu
Leptomeningeal Metastasis
06/23
06/23
ChiCTR2100050095: A single-arm, multi-center, prospective clinical study of recombinant human endostatin injection combined with afatinib maleate tablets and Siggio capsules in the second-line treatment of advanced squamous cell carcinoma of the lung

Not yet recruiting
4
30
 
recombinant human endostatin injection combined with afatinib dimaleate tablets and tegafur, gimeracil and oteracil potassium capsules
The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, China International Medical Exchange Foundation - Simcere Clinical Research Special Fund
advanced lung squamous cell carcinoma
 
 
NCT04814056: To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

Not yet recruiting
4
15
RoW
Afatinib Dimaleate, GIOTRIF®
Shanghai Chest Hospital
NRG1-fused Non-small Cell Lung Cancer
09/23
01/24
NCT04413201: AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

Active, not recruiting
4
34
Europe
Afatinib, Osimertinib
Michael Hopp, Boehringer Ingelheim
Non-squamous NSCLC
12/26
12/26
ACHILLES , jRCTs031180175: study/TORG1834 (study/TORG1834)

Active, not recruiting
3
106
Japan
Gilotrif (afatinib) - Boehringer Ingelheim, cisplatin - Generic mfg., carboplatin - Generic mfg., pemetrexed - Generic mfg.
Niigata Cancer Center Hospital
Advanced non-small cell lung cancer
 
 
CTR20212176: Phase III clinical trial of FHND9041 capsule

Recruiting
3
350
China
FHND9041 - Sino Biopharm, Gilotrif (afatinib) - Boehringer Ingelheim
Jiangsu Zhengda Fenghai Pharmaceutical Co., Ltd.
Non-small cell lung cancer;Oncology
 
 
NCT01853826 / 2009-017661-34: An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Completed
3
481
Europe, RoW
Afatinib, Giotrif®
Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
03/24
03/24
LUX-Head&Neck 3, NCT01856478: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Completed
3
340
RoW
methotrexate, afatinib
Boehringer Ingelheim
Head and Neck Neoplasms
08/18
10/24
FHND9041, NCT06759857: Versus Afatinib for Non-small Cell Lung Cancer

Enrolling by invitation
3
350
RoW
FHND9041, Afatinib
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
03/25
05/25
ERIS, NCT06486142: EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

Recruiting
3
200
Europe
Afatinib/Dacomitinib, Study participants receiving afatinib or dacomitinib until tumor progression/other reasons, Osimertinib, Study participants receiving osimertinib until tumor progression/other reasons
Region Skane, Swedish Lung Cancer Study Group
Non-Small Cell Lung Cancer
09/28
09/28
FHND9041, ChiCTR2100050397: A randomized, open, positives parallel-controlled, multicenter phase III clinical trial to evaluate the efficacy and safety of versus afatinib in first-line treatment of EGFRm+ locally advanced or metastatic non-small cell lung cancer

Recruiting
3
350
 
Afatinib 40mg, orally taken once daily ;FHND9041 80mg, orally taken once daily
Cancer Hospital Chinese Academy of Medical Sciences; Nanjing Chuangte Pharmaceutical Technology Co., Ltd., Self-funded
Non-small cell lung cancer
 
 
NCT02438722: S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Active, not recruiting
2/3
174
US
Afatinib Dimaleate, (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate), BIBW 2992MA2, BIBW2992 MA2, Gilotrif, Cetuximab, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Laboratory Biomarker Analysis
SWOG Cancer Research Network, National Cancer Institute (NCI)
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
09/18
06/25
Drugs-SNPs, NCT05987956: Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms

Not yet recruiting
2/3
600
US
Alectinib - Usual, Usual ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily, Alectinib - Study, Study ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, UnitedHealthcare
Non-small Cell Lung Cancer
11/25
12/25
REAL, UMIN000049225: Rechallenge of afatinib for EGFR mutated non-small cell lung cancer previously treated with osimertinib

Enrolling by invitation
2
30
Japan
Gilotrif (afatinib) - Boehringer Ingelheim
Shinshu University School of Medicine
Non-small cell lung cancer
 
 
WJOG10818L, jRCTs051180009: Trial of the alternative therapy with osimeritinib and afatinib for NSCLC with EGFR mutation (Alt trial)

Completed
2
40
Japan
Tagrisso (osimertinib) - AstraZeneca, Gilotrif (afatinib) - Boehringer Ingelheim
Kindai University Hospital, Department of Medical Oncology, Nippon Boehringer Ingelheim Co., Ltd.
Non-Small Cell Lung Cancer
 
 
YAMATO, jRCTs031200021: A Randomized Phase II Study of Switching Therapy from Afatinib to Osimertinib in the Initial Treatment of Epidermal Growth Factor Receptor (EGFR) Gene Mutation-Positive Non-Squamous Non-Small Cell Lung Cancer (TORG1939/WJOG12919L)

Completed
2
110
Japan
Gilotrif (afatinib) - Boehringer Ingelheim
Kansai Medical University Hospital
Lung cancer
 
 
2006-004528-35: A multicenter, randomized, open label phase II trial evaluating the efficacy and safety of mFOLFOX7 plus weekly alternating sequential oral administration of BIBF 1120 250 mg twice daily and BIBW 2992 50 mg once daily (BB) versus mFOLFOX7 alone as first-line therapy in patients with metastatic colorectal cancer.

Ongoing
2
120
Europe
BIBF 1120, 50 mg, BIBF 1120, 200 mg, BIBW 2992, 5 mg, BIBW 2992, 20 mg, BIBF 1120, BIBW 2992, Capsule, soft, Film-coated tablet, Marca comercial no especificada - Ver sección D.2.2, Marca comercial no especificada- ver sección D.2.2
Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim France SAS, Boehringer Ingelheim España, S.A., , Boehringer Ingelheim España, S.A.
Metastatic colorectal carcinoma, Metastatic colorectal carcinoma Cáncer colo-rectal metastásico., Diseases [C] - Cancer [C04]
 
 
NCT02430727: The Safety and Efficacy Study of Afatinib (CT) Compared With Afatinib (GIOTRIF) in Patients With Solid Tumors (Including Mutations Identified EGFR)

Active, not recruiting
2
148
RoW
Afatinib (CT), BIBW 2992, GIOTRIF, Afatinib
Cancer Centre of Monoclonal Therapy, LLC, Boehringer Ingelheim, NCRI Clinical Studies Groups
Solid Tumors, Glioblastoma
07/15
11/18
2012-004537-16: ABLE Trial – Afatinib Before Lung surgEry

Ongoing
2
69
Europe
Afatinib(Tomtovok), BIBW 2992,
University of Leeds, Boehringer Ingleheim Ltd.
Non-small cell lung cancer
 
 
2014-005364-14: The role of Afatinib to come to radical surgery in patients with non-squamous lung cancer with EGFR gene mutation. Il ruolo di Afatinib per giungere alla chirurgia radicale in pazienti con tumore polmonare non squamoso con mutazione del gene EGFR

Ongoing
2
46
Europe
GIOTRIF 40 MG, GIOTRIF 20 MG, GIOTRIF 30 MG, [GIOTRIF 40 MG], [GIOTRIF 20 MG], [GIOTRIF 30 MG], Coated tablet, GIOTRIF - 40 MG - COMPRESSA RIVESTITA CON FILM - BLISTER DIVISIBILE (PVC/PVDC) 28X1 COMPRESSE, GIOTRIF - 20 MG - COMPRESSA RIVESTITA CON FILM - BLISTER DIVISIBILE (PVC/PVDC) 28X1 COMPRESSE, GIOTRIF - 30 MG - COMPRESSA RIVESTITA CON FILM - BLISTER DIVISIBILE (PVC/PVDC) 28X1 COMPRESSE
ISTITUTO EUROPEO DI ONCOLOGIA, Boehringer Ingelheim
Patients with stage IIIA or stage IIIB N2 requiring neoadjuvant treatment for pN2 non squamous non small cell lung cancer (NSCLC) with EGFR-activating mutations Pazienti con tumore polmonare non a piccole cellule (NSCLC) di tipo non squamoso stadio IIIA o stadio IIIB N2 che richiede un trattamento neoadiuvante pN2 con mutazione attivante del gene EGFR., Patients with non-squamous lung cancer with EGFR gene mutation. Pazienti con tumore polmonare non squamoso con mutazione del gene EGFR, Diseases [C] - Cancer [C04]
 
 
2016-003411-34: Precision 2: an open explorative phase II, open label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation.

Ongoing
2
87
Europe
afatinib, BIBW 2992, Film-coated tablet, GIOTRF
BSMO, UZ Brussel
cancers harbouring an EGFR mutation (excluding non-squamous non- small cell lung cancer, a registered indication), a HER2 mutation or a HER3 mutation, cancers harbouring an EGFR mutation (excluding non-squamous non- small cell lung cancer, a registered indication), a HER2 mutation or a HER3 mutation, Diseases [C] - Cancer [C04]
 
 
ABCD-study, UMIN000030545: Afatinib plus Bevacizumab Combination after osimertinib failure for aDvanced EGFR-mutant non-small cell lung cancer: a multicenter prospective single arm phase II study

Ongoing
2
26
Japan
Gilotrif (afatinib) - Boehringer Ingelheim, Avastin (bevacizumab) - Roche
Hanshin Oncology Group, Boehringer Ingelheim Japan
Advanced EGFR-mutant non-small cell lung cancer
 
 
EAY131-A, NCT06385483: Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Active, not recruiting
2
19
US
Afatinib, BIBW 2992, BIBW-2992, BIBW2992, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
12/22
12/25
2012-000167-25: A multicentric randomized phase II study evaluating dual targeting of the EGFR using the combination of cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer.

Not yet recruiting
2
75
Europe
BIBW2992, AFATINIB, Tablet
UNICANCER, Boerhinger Ingelheim
Refractory wtKRAS metastatic colorectal cancer, Diseases [C] - Cancer [C04]
 
 
TOPGAN2023-01, R000019088: Dose-escalation Study of Afatinib in Elderly Patients with EGFR mutation for Non-Small Cell Lung Cancer

Completed
2
18
Japan
Gilotrif (afatinib) - Boehringer Ingelheim
Hirosaki University Graduate School of Medicine, Hirosaki University Graduate School of Medicine
Non-small cell lung cancer
 
 
The ASCENT Trial, NCT01553942: Afatinib With CT and RT for EGFR-Mutant NSCLC

Active, not recruiting
2
19
US
Afatinib, Radiation, Cisplatin, Pemetrexed, Surgery
Massachusetts General Hospital
Lung Cancer
12/24
12/24
NCT03810872: An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

Recruiting
2
87
Europe
Afatinib, Paclitaxel
AZ-VUB
Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation
12/20
12/22
EAY131-B, NCT04439136: Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Active, not recruiting
2
40
US
Afatinib Dimaleate, (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate), BIBW 2992MA2, BIBW2992 MA2, Gilotrif
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
01/21
03/26
2021-003755-41: ERIS- a national study on characterization of EGFR-positive lung cancer

Not yet recruiting
2
200
Europe
Tablet, VIZIMPRO, GIOTRIF
Region Skåne, Sjöberg Foundation, Kamprad Foundation, The Swedish cancer society
EGFR-mutated non-small cell lung cancer (NSCLC) not amenable for curative treatment intention and candidates for EGFR-inhibitor in first line., Lung cancer with an EGFR-mutation., Diseases [C] - Cancer [C04]
 
 
Neoafa, NCT04470076: Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation

Not yet recruiting
2
30
NA
Neoadjuvant treatment: Afatinib, pemetrexed, gemcitabine, cisplatin, carboplatin, Surgical treatment, Adjuvant treatment:afatinib
Fifth Affiliated Hospital, Sun Yat-Sen University
Non Small Cell Lung Cancer, Surgery, EGFR Activating Mutation, Chemotherapy, EGFR TKI
12/21
07/23
ChiCTR1800019638: Apatinib combined with Docetaxel compared to Docetaxel monotherapy in the treatment of patients with advanced lung squamous cell carcinoma: a prospective, phase II randomized controlled trial

Not yet recruiting
2
200
 
Afatinib and Docetaxel ;Docetaxel
Fujian Tumor Hospital; Fujian Tumor Hospital, Patients at his own expense
squmous cell lung cancer
 
 
AFACET, NCT03727724 / 2018-001521-97: Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer

Completed
2
37
Europe
Afatinib, Cetuximab
The Netherlands Cancer Institute, Boehringer Ingelheim, Merck Serono International SA
Carcinoma, Non-Small-Cell Lung
09/22
09/22
NCT04880811: Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Not yet recruiting
2
43
RoW
Afatinib, Toripalimab
Peking University
Esophageal Squamous Cell Carcinoma
10/22
05/23
TRUMP, NCT03574402: Phase II Umbrella Study Directed by Next Generation Sequencing

Recruiting
2
400
RoW
Avitinib Maleate, AC0010, Afatinib, Giotrif, Crizotinib, Xalkori, X-396, ensartinib, Chidamide, Epidaza, Pyrotinib Maleate, SHR1258, AZD3759, Pirotinib, KBP-5209, Nimotuzumab, Pemetrexed, LY231514, Cisplatin, CDDP, Sintilimab, Gemcitabine, LY188011, Carboplatin, NSC 241240
Guangdong Association of Clinical Trials, Chinese Thoracic Oncology Group
Carcinoma, Non-Small-Cell Lung
12/22
12/24
NCT01522768: Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

Checkmark ASCO-GI 2014
Jan 2014 - Jan 2014: ASCO-GI 2014
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
2
42
US
Afatinib and Paclitaxel
Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, University of Southern California, Dana-Farber Cancer Institute, United States Department of Defense
Esophageal Cancer, Gastric Cancer
02/23
02/23
BEAR, NCT04839471: BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma ( Study)

Completed
2
49
RoW
BI-754091 plus afatinib
National Health Research Institutes, Taiwan, Taipei Veterans General Hospital, Taiwan, Chang Gung Memorial Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
07/23
06/24
MOBILITY3, NCT02506517: A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

Completed
2
12
Canada
Afatinib, GIOTRIF
University Health Network, Toronto, Boehringer Ingelheim
Solid Tumors
05/23
05/23
NCT04183712: Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

Recruiting
2
102
RoW
gemcitabine and oxaliplatin., Gemzar(Eli Lilly and Company) and Aiheng(Jiangsu Hengrui Medicine Co., Ltd.), Afatinib, Gilotrif(Boehringer-Ingelheim)
Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital, Ruijin Hospital, RenJi Hospital, Qilu Hospital of Shandong University, The First Affiliated Hospital of Anhui Medical University, Shanghai East Hospital of Tongji University, Changshu Affiliated Hospital of Soochow University, Qinghai People's Hospital, The Second People's Hospital of Baoshan, Yunnan Province, Lanzhou University Second Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The First People's Hospital of Nantong
Gallbladder Carcinoma
06/25
12/25
NCT03239015: Efficacy and Safety of Precision Therapy in Refractory Tumor

Recruiting
2
300
RoW
Gefitinib, Erlotinib, Afatinib, Trastuzumab, Oxazolidine, Olaparib, Everolimus, Cabozantinib, Vemurafenib, Dabrafenib, Palbociclib, PD-1/L1 inhibitor plus anti-angiogenic agent
Baodong Qin
Rare Tumor, Refractory Tumor
06/23
12/23
NCT03083678 / 2016-002766-31: Afatinib in Locally Advanced and Metastatic Chordoma

Completed
2
43
Europe
Afatinib, Giotrif
Leiden University Medical Center, Chordoma Foundation, Boehringer Ingelheim
Chordoma
01/25
01/25
neoCHANCE-2, NCT05516589: Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC

Recruiting
2
28
RoW
Nab-paclitaxel, Albumin-bound paclitaxel, Abraxane, Cisplatin, CDDP, Tislelizumab, BGB-A317, Afatinib
West China Hospital
Head and Neck Squamous Cell Carcinoma
08/23
08/24
neoCHANCE-1, NCT05517330: Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma

Recruiting
2
23
RoW
Tislelizumab, BGB-A317, Afatinib
West China Hospital
Head and Neck Cancer
08/23
08/24
NCT04533321: A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma

Not yet recruiting
2
20
RoW
Afatinib
National University Hospital, Singapore
Squamous Cell Carcinoma
09/23
09/23
DARWIN1, NCT02183883: Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity

Completed
2
12
Europe
Afatinib, Giotrif
University College, London, Boehringer Ingelheim
Non-small Cell Lung Cancer
03/23
03/23
HER2BAT, NCT04158947: A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone

Recruiting
2
130
RoW
Afatinib, BIBW 2992, T-DM1, Trastuzumab emtansine
xuexin he
HER2-positive Breast Cancer, Brain Metastases
12/23
03/24
NL74383.029.20, NCT05298176 / 2020-003025-37: Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors

Completed
2
5
Europe
Afatinib, Osimertinib, Carboplatin and Pemetrexed
Amsterdam UMC, location VUmc, Boehringer Ingelheim
Non-Small Cell Lung Cancer
04/24
04/24
NCT02122172: Afatinib in Advanced Refractory Urothelial Cancer

Terminated
2
32
US
afatinib dimaleate, afatinib, BIBW 2992 MA2, Gilotrif, laboratory biomarker analysis
University of Chicago, National Cancer Institute (NCI)
Distal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Urethral Cancer, Stage III Bladder Cancer, Stage III Urethral Cancer, Stage IV Bladder Cancer, Stage IV Urethral Cancer, Ureter Cancer
04/24
04/24
NCT02491099: A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

Recruiting
2
50
US
Afatinib, Irreversible Human Epidermal Growth Factor
Yale University, Boehringer Ingelheim
HER2/Neu+ Uterine Serous Carcinoma
07/25
07/25
NCT05215548: Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Active, not recruiting
2
100
RoW
therapeutic thoracic surgery, Afatinib, Giotrif, BIBW 2992
National Taiwan University Hospital
NSCLC Stage IV
10/26
10/27
NCT05070403: Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Recruiting
2
25
US
Afatinib 40 MG
H. Lee Moffitt Cancer Center and Research Institute, Boehringer Ingelheim
Squamous Cell Carcinoma
03/26
03/28
NCT04497584: Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

Recruiting
2
37
US
Afatinib + Prednisone
University of Texas Southwestern Medical Center
Advanced Squamous Non Small Cell Lung Cancer
09/25
09/26
NCT02979977: Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Active, not recruiting
2
50
US
cetuximab, Erbitux, afatinib, GIOTRIF or GILOTRIF
Yale University, National Comprehensive Cancer Network, Boehringer Ingelheim
Squamous Cell Cancers of the Head and Neck
03/25
12/27
NCT05267288: Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Recruiting
2
30
RoW
afatinib, bevacizumab
Qingdao Central Hospital
PFS
12/24
06/25
NCT04410653: Afatinib in Advanced NRG1-Rearranged Malignancies

Completed
2
3
Europe
Afatinib 40 MG
German Cancer Research Center, German Consortium for Translational Cancer Research
Metastatic and Locally Advanced NRG1-rearranged Malignancies
10/23
10/23
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
4200
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
12/27
12/28
NCT06709859: Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Not yet recruiting
2
30
RoW
Afatinib plus chemotherapy as conversion treatment
Shandong Public Health Clinical Center
Carcinoma, Non-Small-Cell Lung
05/26
12/27
NCT06804850: Neoadjuvant Low-Dose Radiotherapy Plus Targeted-Immunotherapy vs Targeted-Immunotherapy Monotherapy in Resectable HNSCC: A Randomized Trial

Recruiting
2
98
RoW
Tislelizumab, Immunotherapy, Afatinib, Targeted therapy, Low dose radiotherapy, Radiotherapy
West China Hospital
Head and Neck Cancer
06/26
06/26
NCT05818982: To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC

Recruiting
2
72
RoW
Afatinib, Irinotecan
Peking University
Advanced Esophageal Squamous Cell Carcinoma
02/25
02/26
NCT05865132: Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

Recruiting
2
30
RoW
Palbociclib, Afatinib
AIPING ZHOU
Esophagus Squamous Cell Carcinoma
04/25
04/26
UPSTREAM, NCT03088059 / 2017-000086-74: Biomarker-based Study in R/M SCCHN

Checkmark Data from UPSTREAM trial in combination with monalizumab for SCCHN
Oct 2019 - Oct 2019: Data from UPSTREAM trial in combination with monalizumab for SCCHN
Active, not recruiting
2
340
Europe
Afatinib, Palbociclib, standard of care, IPH2201, Monalizumab, Durvalumab, Niraparib, INCAGN01876
European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma, Squamous Cell of Head and Neck
06/25
12/25
NCT05519917: Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma

Not yet recruiting
2
20
RoW
Afatinib
Huashan Hospital, Boehringer Ingelheim
Chordoma of Clivus
06/25
12/25
NCT05588609: Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Active, not recruiting
2
90
US
Afatinib Oral Tablet, GILOTRIF®, GIOTRIF®, Enzalutamide Pill, XTANDI®, Abiraterone acetate tablets, ZYTIGA®, MCLA-128, Zenocutuzumab
Merus N.V.
NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
10/25
03/26
NCI-MATCH, NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Checkmark Approved in combination with Trametinib for adult and pediatric patients with BRAF V600E solid tumors
Jan 2023 - Jan 2023: Approved in combination with Trametinib for adult and pediatric patients with BRAF V600E solid tumors
Checkmark Approved in combination with for Mekinist for BRAF V600E solid tumors
Jun 2022 - Jun 2022: Approved in combination with for Mekinist for BRAF V600E solid tumors
Checkmark Results from arm Z1D-a subprotocol of the NCI-MATCH study in mismatch repair-deficient non-colorectal cancers
More
Active, not recruiting
2
6452
US, RoW
Adavosertib, AZD 1775, AZD-1775, AZD1775, MK 1775, MK-1775, MK1775, Afatinib, BIBW 2992, BIBW-2992, BIBW2992, Afatinib Dimaleate, (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate), BIBW 2992MA2, BIBW2992 MA2, Gilotrif, Binimetinib, ARRY 162, ARRY 438162, ARRY-162, ARRY-438162, ARRY162, ARRY438162, MEK 162, MEK-162, MEK162, Mektovi, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capivasertib, AZD 5363, AZD-5363, AZD5363, Truqap, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Copanlisib, BAY 80 6946, BAY 80-6946, BAY 806946, BAY-80-6946, BAY806946, PI3K Inhibitor BAY 80-6946, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Crizotinib, Alkixen, Crizocent, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Dabrafenib, BRAF Inhibitor GSK2118436, GSK 2118436, GSK 2118436A, GSK-2118436, GSK-2118436A, GSK2118436, GSK2118436A, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Defactinib, PF-04554878, VS-6063, Defactinib Hydrochloride, Echocardiography Test, EC, Echocardiography, Erdafitinib, Balversa, JNJ 42756493, JNJ-42756493, JNJ42756493, Fexagratinib, ABSK-091, ABSK091, AZD4547, FGFR Inhibitor AZD4547, KB-74810, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Laboratory Biomarker Analysis, Larotrectinib, ARRY 470, LOXO 101, LOXO-101, LOXO101, Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Osimertinib, AZD 9291, AZD-9291, AZD9291, Mereletinib, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, PD0332991, Pertuzumab, 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440, PI3K-beta Inhibitor GSK2636771, GSK-2636771, GSK2636771, Radiologic Examination, Radiologic Evaluation, Radiologic Exam, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Relatlimab, BMS 986016, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer, Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228, Sunitinib Malate, SU 011248, SU 11248, SU-011248, SU-11248, SU011248, SU11248, sunitinib, Sutent, Taselisib, GDC-0032, RO5537381, Trametinib, GSK 1120212, GSK 212, GSK-1120212, GSK-212, GSK1120212, GSK212, JTP 74057, JTP-74057, JTP74057, MEK Inhibitor GSK1120212, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, HLX 02, HLX-02, HLX02, Kanjinti, Ogivri, Ontruzant, PF 05280014, PF-05280014, PF05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO 132365, PRO-132365, PRO132365, RO5304020, T-DM1, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Ulixertinib, BVD-523, VRT752271, Vismodegib, Erivedge, GDC 0449, GDC-0449, GDC0449, Hedgehog Antagonist GDC-0449
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
12/25
12/25
NCT06071013: Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Not yet recruiting
2
20
NA
Nintedanib, gefitinib, erlotinib, afatinib
China Medical University Hospital
Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation
08/26
08/26
NCT06062823: Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

Recruiting
2
35
RoW
Afatinib 40 MG, Gilotrif
National University Hospital, Singapore
NSCLC
10/26
12/26
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
2015-001477-41: BI 1361849 (CV9202) + afatinib compared with placebo + afatinib in first-line NSCLC harbouring common EGFR mutations BI 1361849 (CV9202) + afatinib comparado con placebo + afatinib como tratamiento de primera línea en pacientes con NSCLC portadores de mutaciones comunes del EGFR.

Ongoing
1/2
120
Europe
BI 1361849, Afatinib, BI 1361849, BIBW 2992, Powder and solvent for solution for injection, Film-coated tablet, GIOTRIF 20 mg film-coated tablets, GIOTRIF 30 mg film-coated tablets, GIOTRIF 40 mg film-coated tablets
Boehringer Ingelheim España, S.A., Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim España, S.A., Boehringer Ingelheim Pharma GmbH & Co. KG
Advanced non-small cell lung cancer (adenocarcinoma) stage IV. Cáncer de pulmón no microcítico metastásico (adenocarcinoma) estadio IV ., Advanced lung cancer with metastases. Cáncer de pulmón avanzado con metástasis., Diseases [C] - Cancer [C04]
 
 
CamBMT1, NCT02768337: Cambridge Brain Mets Trial 1

Terminated
1/2
26
Europe
Afatinib, Giotrif, 2 Gy targeted radiotherapy, 4 Gy targeted radiotherapy
Cambridge University Hospitals NHS Foundation Trust, Boehringer Ingelheim, Cancer Research UK, University of Cambridge, The Brain Tumour Charity
Lung Cancer, Breast Cancer, Brain Cancer, Advanced Breast Cancer, Advanced Lung Cancer
08/20
08/21
KRYSTAL-1, NCT03785249: Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation

Jul 2023 - Sep 2023: Approval in EU for 2L+ NSCLC
Checkmark Approved for 2L KRASG12C-mutated locally advanced or metastatic NSCLC based on KRYSTAL-1 study
Dec 2022 - Dec 2022: Approved for 2L KRASG12C-mutated locally advanced or metastatic NSCLC based on KRYSTAL-1 study
Checkmark Data from KRYSTAL-1 trial for colorectal cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from KRYSTAL-1 trial for colorectal cancer at ESMO 2022
More
Recruiting
1/2
822
US
MRTX849, Pembrolizumab, Cetuximab, Afatinib
Mirati Therapeutics Inc.
Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
07/25
01/26
AFAN, NCT06648096: Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Not yet recruiting
1/2
25
Europe
Afatinib
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, MFAR Clinical Research S.L.
Fanconi Anemia, Head and Neck Squamous Cell Carcinoma
12/28
12/28
NCT06753747: A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

Not yet recruiting
1/2
45
RoW
Palbociclib, Afatinib(30mg), Afatinib(40mg), Afatinib(RP2D)
West China Hospital
Esophagus Cancer
04/27
04/28
NCT06085755: Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

Recruiting
1/2
61
RoW
Trastuzumab deruxtecan, T-DXd, Afatinib, Giotrif
Jeeyun Lee
Stomach Neoplasm
12/25
12/26
CSWOG2019001, ChiCTR1800020396: Afatinib combined with Docetaxel compared to Docetaxel or afatinib monotherapy in the treatment of patients with advanced lung squamous cell carcinoma: a prospective, phase II randomized controlled trial

Not yet recruiting
1
244
 
Afatinib combined Docetaxel ;Afatinib ;Docetaxel
Fujian Tumor Hospital; Fujian Tumor Hospital, at his own expense
squamous cell lung carcinoma
 
 
NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Recruiting
1
48
RoW
JMT101, Afatinib or Osimertinib
Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
12/21
06/22
DPTA, NCT03827070: Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma

Active, not recruiting
1
12
RoW
Afatinib, BIBW2992, Talcum powder, Talc
Center Trials & Treatment Europe, Center Trials & Treatment
Non Small Cell Lung Cancer
02/23
07/23
NCT05164848: JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy

Recruiting
1
50
RoW
JMT101, Afatinib
Peking University
Esophageal Squamous Carcinoma
10/23
10/23
NCT06302621: Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Recruiting
1
70
US
Afatinib, Gilotrif™, Pemigatinib, Pemazyre
Massachusetts General Hospital, Boehringer Ingelheim, Incyte Corporation
Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Cholangiocarcinoma
12/24
12/25
NCT06494189: Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

Recruiting
1
29
RoW
Tislelizumab, Afatinib, Low dose radiotherapy
West China Hospital
Head and Neck Cancer
07/25
12/25
NCT06741982: A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

Recruiting
1
21
RoW
Lysogenic HSV virus., Biological agent, Tislelizumab, Immunotherapy, Afatinib, Targeted therapy
West China Hospital
HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy, Targeted Therapy
12/26
12/26
EDDIS-a1, NCT06897735: Exploratory Study of Inhaled Afatinib Dimaleate PK Profile

Not yet recruiting
1
24
RoW
Afatinib Dimaleat, BIBW2992 Dimaleate, Gilotrif, Afatinib Dimaleate, inhalation of afatinib dimaleate
Petrov, Andrey
Lung Cancer, Oral Cancer, Melanoma
06/25
07/25
NCT05927844: XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma

Not yet recruiting
1
20
NA
XH-30002 capsule, Afatiinb tablet
Fujian Cancer Hospital
Esophageal Squamous Cell Carcinoma
06/25
06/25
SMMART, NCT03878524: Serial Measurements of Molecular and Architectural Responses to Therapy () PRIME Trial

Terminated
1
2
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Abiraterone, CB 7598, Afatinib, BIBW 2992, BIBW2992, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Zirabev, Anti-VEGF Monoclonal Antibody SIBP04, SIBP 04, SIBP-04, SIBP04, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Biospecimen Collection, Biological Sample Collection, Specimen Collection, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Cabozantinib, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, 934660-93-2, Copanlisib, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Dacomitinib, EGFR Inhibitor PF-00299804, PF-00299804, PF-00299804-03, PF-299804, Vizimpro, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, 1297538-32-9, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, 1428935-60-7, Enasidenib, AG-221, CC-90007 Free Base, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Enzalutamide, ASP9785, MDV3100, Xtandi, Erlotinib, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Idelalisib, CAL-101, GS 1101, GS-1101, Phosphoinositide-3 Kinase Delta Inhibitor CAL-101, Zydelig, Imatinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Leucovorin, Folinic acid, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, PF-06463922, Losartan, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Neratinib, (2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, HKI 272, HKI-272, PB 272, PB-272, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Panobinostat, Faridak, LBH589, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pertuzumab, 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, HLX11, Ponatinib, AP-24534, AP24534, Quality-of-Life Assessment, Quality of Life Assessment, Regorafenib, BAY 73-4506, REGORAFENIB ANHYDROUS, Stivarga, Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Sorafenib, BA4 43 9006, BAY 43-9006, Bay-439006, Sunitinib, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Tretinoin, 2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-, Aberel, Airol, Aknoten, all trans-Retinoic acid, All-trans Retinoic Acid, All-trans Vitamin A Acid, all-trans-Retinoic acid, all-trans-Vitamin A acid, ATRA, Avita, beta-Retinoic Acid, Cordes Vas, Dermairol, Epi-Aberel, Eudyna, Renova, Retin-A, Retin-A MICRO, Retin-A-Micro, Retinoic Acid, Retisol-A, Ro 5488, Stieva-A, Stieva-A Forte, Trans Retinoic Acid, Trans Vitamin A Acid, trans-Retinoic Acid, Tretinoinum, Vesanoid, Vitamin A Acid, Vitamin A acid, all-trans-, Vitinoin, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
OHSU Knight Cancer Institute, Oregon Health and Science University
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
12/20
12/20
CodeBreak101, NCT04185883 / 2020-004721-23: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Checkmark Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Checkmark Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Checkmark Presentation of data from CodeBreak 101 and CodeBreak 100 in combination with Keytruda and Tecentriq for 2L NSCLC at IASLC-WCLC 2022
More
Recruiting
1
1200
Europe, Canada, Japan, US, RoW
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Amgen, Amgen Inc, Amgen Inc.
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
06/26
12/27
NCT05432518: Pilot Trial for Treatment of Recurrent Glioblastoma

Recruiting
1
10
Canada
Afatinib, Giotrif, Dasatinib, Sprycel, Palbociclib, Ibrance, Everolimus, Teva-everolimus, Olaparib, Lynparza
AHS Cancer Control Alberta, Tom Baker Cancer Centre
Glioblastoma, Recurrent Disease, Recurrent Glioblastoma
07/27
12/27
ChiCTR2200067154: Bioequivalence study of Afatinib maleate tablets

Completed
N/A
32
 
The selected subjects entered the Phase I ward 1 day before the first cycle of the test, and the subjects fasted for at least 10 hours ning of the administration day, the test preparation was orally adminiovernight before taking the drug. After a blank blood sample was collected in the morsterermd. ;The selected subjects entered the Phase I ward 1 day before the first cycle of the test, and the subjects fasted for at least 10 hours overnight before taking the drug. After a blank blood sample was collected in the morning of the administration day, the reference preparation was orally administere
Shanghai Pudong New Area People's Hospital; Shanghai Pudong New Area People's Hospital, Jiangxi Shanxiang Pharmaceutical Co., Ltd.
NA
 
 
Gio-Tag Japan, UMIN000037452: Japanese A Multicenter Prospective Observational Study to Evaluate the Efficacy of Sequential Administration From Afatinib to Osimertinib in EGFR Mutation-Positive Non-Small Cell Lung Cancer

Recruiting
N/A
120
Japan
Gilotrif (afatinib) - Boehringer Ingelheim, Tagrisso (osimertinib) - AstraZeneca
HANSHIN Oncology Group, Boehringer Ingelheim
Non-small cell lung cancer
 
 
ChiCTR1800018149: A multicentre, open-label, randomised, controlled trial for the effect and safety of Afatinib with Nivolumab in the treatment of gallbladder carcinoma with ERBB2/3 mutation

Not yet recruiting
N/A
522
China
treating with Afatinib and Nivolumab ;treating with Afatinib ;treating with GEMOX
Xinhua Hospital affiliated to Shanghai Jiaotong University, School of Medicine ; Xinhua Hospital affiliated to Shanghai Jiaotong University, School of Medicine, Shanghai Hospital Development Center
gallbladder carcinoma
 
 
ChiCTR2100047133: Multicentre, prospective, real-world clinical study of afatinib or gefitinib in combination with first-line chemotherapy for advanced EGFR mutant non-squamous NSCLC

Recruiting
N/A
1000
 
Nil ;Nil
Shandong Cancer Hospital; Shandong Cancer Hospital, Qilu Pharmaceutical Co., Ltd
Lung cancer
 
 
ChiCTR1900024983: A non-interventional, single-arm, prospective clinical study for the efficacy and safety of low-dose alfaatinib combined with pemetrexed and carboplatin in first-line treatment of advanced EGFR mutant non-squamous non-small cell lung cancer

Recruiting
N/A
100
 
Afatinib, Pemetrexed and Carboplatin
Shandong Cancer Hospital; Shandong Cancer Hospital, Self-finance
Lung Cancer
 
 
NCT05107193: Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)

No Longer Available
N/A
NA
afatinib, GILOTRIF®
Boehringer Ingelheim
Solid Tumors
 
 
NCT03908892: Effect of Zanthoxylum Nitidum Tincture for Paronychia Caused by Afatinib

Recruiting
N/A
110
RoW
zanthoxylum nitidum tincture, tetracycline ointment
Guangzhou University of Traditional Chinese Medicine
Paronychia
12/22
12/22
BELLA, NCT04575415: Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

Recruiting
N/A
272
RoW
Bevacizumab, Avastin, Erlotinib, Tarceva, Gefitinib, Iressa, Icotinib, Conmana, Afatinib, Gilotrif, Dacomitinib, Vizimpro, Osimertinib, Tagrisso
Guangdong Association of Clinical Trials
NSCLC
05/23
12/23
ChiCTR2000034451: Bevacizumab combined with afatinib for first-line treatment of locally advanced or advanced EGFR mutation-positive NSCLC patients: the effectiveness and safety database management platform construction project

Not yet recruiting
N/A
50
 
afatinib combined with bevacizumab
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Association of Oncology
NSCLC
 
 
NCT04795245: Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Completed
N/A
805
Japan
afatinib, Giotrif®
Boehringer Ingelheim
Non-squamous, Non-Small Cell Lung Cancer
10/23
10/23
START, NCT04206787: The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

Completed
N/A
72
RoW
Afatinib, Giotrif®
Boehringer Ingelheim
Non-squamous, Non-Small Cell Lung Cancer
12/23
12/23
ChiCTR2200057280: Efficacy and safety of low-dose afatinib combined with bevacizumab and pemetrexate in first-line treatment of stage IV lung adenocarcinoma with EGFR mutation

Recruiting
N/A
100
 
low-dose alfaatinib combined with bevacizumab and pemetrexed
Shandong Cancer Hospital; Shandong Cancer Hospital, self-funded
Lung Cancer
 
 
ChiCTR2100042399: Anlotinib combined with afatinib in the third-line treatment of advanced lung squamous cell carcinoma

Not yet recruiting
N/A
35
 
Anlotinib combined with afatinib
Cancer Center of Yibin Second People's Hospital; Cancer Center of Yibin Second People's Hospital, None
Lung squamous cell carcinoma that failed second-line chemotherapy
 
 
 

Download Options